

Special Issue

Global Analysis of Tracking the Evolution of SARS-CoV-2 Variants

Message from the Guest Editor

SARS-CoV-2, a positive-sense α -coronavirus, is the etiological agent of COVID-19. Although it possesses an error-prone viral RNA-dependent RNA polymerase with limited 3'-5' exoribonuclease activity, it can cause progeny viruses with new mutations, affecting its infectivity, transmissibility, and virulence. Moreover, recently, a sharp decline in PCR testing due to high cost and reliance on antigen testing kits could lead to the potential underreporting of new emerging variants. Therefore, the continuous monitoring and tracking of new variants on a globe scale, as well as the characterization of mutations, is crucial because of their effect on adaptive immunity, neutralizing antibody response, and impact on vaccine efficacy. The detailed maps of mutations highlighting their prospective role in therapeutics and vaccine development can better prepare us for future waves of continuously evolving SARS-CoV-2. With this aim, we invite original research and review articles which address the tracking and genomic surveillance of emerging variants, their virulence, transmissibility, mathematical modeling, and therapeutic aspects of COVID-19.

Guest Editor

Dr. Muhammad Atif Zahoor

Viral Hepatitis Care Network (VIRCAN) Study Group, Toronto Centre for Liver Disease, Toronto, ON M5G 2C, Canada

Deadline for manuscript submissions

closed (30 June 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/134954

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).